Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence. - Wikidata - awgldk - TriplyDB

Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence.

Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence.

http://www.wikidata.org/entity/Q34668335

about

Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction Serum non-high-density lipoprotein cholesterol concentration and risk of death from cardiovascular diseases among U.S. adults with diagnosed diabetes: the Third National Health and Nutrition Examination Survey linked mortality study.Elevated fasting insulin predicts the future incidence of metabolic syndrome: a 5-year follow-up study Apolipoprotein E gene polymorphism: effects on plasma lipids and risk of type 2 diabetes and coronary artery disease Prognostic significance of the complex "Visceral Adiposity Index" vs. simple anthropometric measures: Tehran lipid and glucose study Relation of Combined Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B With Atherosclerosis in Adults With Type 1 Diabetes Mellitus Estimation of plasma apolipoprotein B concentration using routinely measured lipid biochemical tests in apparently healthy Asian adults Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians Apolipoprotein E gene polymorphism and risk of type 2 diabetes and cardiovascular disease The atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk, beta-cell function loss and microangiopathy in type 2 diabetes females.Discriminant ratio and biometrical equivalence of measured vs. calculated apolipoprotein B100 in patients with T2DM Quantification of concordance and discordance between apolipoprotein-B and the currently recommended non-HDL-cholesterol goals for cardiovascular risk assessment in patients with diabetes and hypertriglyceridemia Novel unbiased equations to calculate triglyceride-rich lipoprotein cholesterol from routine non-fasting lipids.Validation of a Newly Developed Equation for Estimating Serum Apolipoprotein B: Associations with Cardiovascular Disease Surrogate Markers in Koreans.Blood glucose and insulin and correlation of SLC25A13 mutations with biochemical changes in NICCD patients.Non-high-density lipoprotein cholesterol: An important predictor of stroke and diabetes-related mortality in Japanese elderly diabetic patients Non-HDL-cholesterol to HDL-cholesterol ratio is a better predictor of new-onset non-alcoholic fatty liver disease than non-HDL-cholesterol: a cohort study

P2860

Q21246041-348988E6-0565-4402-9FA3-6B93BBD108A1 Q35081120-8EFFC814-B042-47D4-942D-D4F60AC99011 Q35744930-BC702166-FFF2-4FDA-A34E-711262259830 Q36023835-BF475FCD-303E-4F86-9ADF-699E2BED8893 Q36034940-A05414BF-F8EB-4149-AF81-42B566055DD1 Q36054342-2B09DBF1-7211-4B1A-A820-5AA06398A03C Q36281471-A47C2FE6-D5E5-4000-BA03-02D272C2ADD9 Q36411656-9AE9A5AC-CFA6-4FFE-8F32-CB78F20FF97D Q36443768-137EB26C-62DC-4D10-A32D-01A3AC0499B0 Q36493730-1AD74273-2CCE-497F-AA1B-9308DE020A2C Q36517644-1E8AC00E-4B56-4EB8-B567-427290F9B9D4 Q36697855-8D4E0C71-E785-4A54-9CF6-274BC2BA08C2 Q37135042-0CF8A397-D91C-480D-89E3-230B9B651F8D Q37683866-17E2287E-460C-4D18-8529-3C60DB98DC44 Q41352387-E7ABA1F7-9D81-4E9C-B3C5-373547F2ED26 Q44730334-F485D380-48DF-472A-8E3C-4713168D0EBC Q58207412-B64411B9-EFDD-41CD-8056-547B58002A5F Q58731134-D1395EE5-944B-430B-ACFF-74485E9F54F9

P2860

Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence.

http://www.wikidata.org/entity/Q34668335

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Non-HDL-cholesterol as valid s ...... atio and unbiased equivalence.

@ast

Non-HDL-cholesterol as valid s ...... atio and unbiased equivalence.

@en

Non-HDL-cholesterol as valid s ...... atio and unbiased equivalence.

@nl

type

label

Non-HDL-cholesterol as valid s ...... atio and unbiased equivalence.

@ast

Non-HDL-cholesterol as valid s ...... atio and unbiased equivalence.

@en

Non-HDL-cholesterol as valid s ...... atio and unbiased equivalence.

@nl

prefLabel

Non-HDL-cholesterol as valid s ...... atio and unbiased equivalence.

@ast

Non-HDL-cholesterol as valid s ...... atio and unbiased equivalence.

@en

Non-HDL-cholesterol as valid s ...... atio and unbiased equivalence.

@nl

P1433

Q34668335-BC19F83C-0652-42CA-9AF6-D30087FFF331

P1476

Q34668335-E255224D-21DC-452A-9A15-2DEF7B179364

P2093

Q34668335-0462178F-87D1-4935-AFDB-51752A27CF86

Q34668335-312B85B2-224A-404C-990D-30DA48DB398C

Q34668335-384D7ABC-0451-46B0-B48B-28E5E070C855

Q34668335-5759481D-035C-4732-B89D-613543264E24

P2860

Q34668335-130D05D8-5F05-4178-8576-988770A665F6

Q34668335-13E4C0B3-B257-4D3B-BDEE-52378C0A5633

Q34668335-172BA2E0-EB13-46A1-9BE1-E0977EA5E94F

Q34668335-22394EB0-1F36-4392-9693-F2CE88D93885

Q34668335-24693CCA-1A61-43F4-A0CC-C8AC6D5BAB5E

Q34668335-408A8682-765B-4FA6-AE87-AFC137892333

Q34668335-41866047-F66F-4492-879E-50D932AEDAA2

Q34668335-423786F7-666A-4DB6-9197-59DEAEFEC6F3

Q34668335-4E5EA826-618B-4BCB-A404-F40CBEC8B796

Q34668335-5ED31CDF-1C12-4CA1-9EBC-682A98C206C7

P2888

Q34668335-F59AC21F-2BE9-4CD2-90BD-07AA4F1822C0

P304

Q34668335-26DBC9F1-3D77-403B-BE23-496F8A64FC44

P31

Q34668335-97EF56DA-5111-4A09-A564-1690E18BDBFB

P356

Q34668335-E0FEE740-1095-4DAC-9497-12EF241AE0E9

P407

Q34668335-C47DE7C5-858E-406D-B79A-5B346447CF16

P478

Q34668335-9D6E2180-3816-4AB4-9915-F85561806DCD

P577

Q34668335-BFAAE913-20E4-4186-8DB2-13DF6BFE8E93

P5875

Q34668335-A03499C4-F628-44DD-A55B-A0E98B21D3EF

P6179

Q34668335-2DCD73A5-6B95-4BAE-AF8D-90EB352AAE07

P698

Q34668335-FB163DF8-EA78-4CDB-A709-2771B6442CDC

P921

Q34668335-AF5F3B28-3637-4E94-9F79-79CDA935B038

P932

Q34668335-E917277C-5C74-41E1-8E92-4580D64FD249

P356

1475-2840-10-20

P1433

Cardiovascular Diabetology

P1476

Non-HDL-cholesterol as valid s ...... atio and unbiased equivalence.

@en

P2093

Frank M Sacks

http://www.w3.org/2001/XMLSchema#string

Michel F Rousseau

http://www.w3.org/2001/XMLSchema#string

Michel P Hermans

http://www.w3.org/2001/XMLSchema#string

Sylvie A Ahn

http://www.w3.org/2001/XMLSchema#string

P2860

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes

Comparison of tests of beta-cell function across a range of glucose tolerance from normal to diabetes

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males

Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation.

Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population.

2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations.

Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells.

High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study.

P2888

1475-2840-10-20

P304

20

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1475-2840-10-20

http://www.w3.org/2001/XMLSchema#string

P407

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50225255

http://www.w3.org/2001/XMLSchema#string

P6179

1044134467

http://www.w3.org/2001/XMLSchema#string

P698

21356116

http://www.w3.org/2001/XMLSchema#string

P921

P932

3056766

http://www.w3.org/2001/XMLSchema#string